Mechanism-Based Inactivation of Cytochrome P450 3A4 by 4-Ipomeanol
- 27 January 2004
- journal article
- Published by American Chemical Society (ACS) in Chemical Research in Toxicology
- Vol. 17 (2) , 150-157
- https://doi.org/10.1021/tx034143l
Abstract
Earlier phase I and II clinical studies showed that 4-ipomeanol produced selective hepatotoxicity. To investigate the mechanism of bioactivation of 4-ipomeanol, we thoroughly studied the interaction of 4-ipomeanol with human cytochrome P450 3A4 (EC 1.14.14.1). 4-Ipomeanol produced a time- and concentration-dependent inactivation of P450 3A4. More than 80% of the P450 3A4 activity was lost after its incubation with 4-ipomeanol at the concentration of 75 microM in 12 min. The inactivation was characterized by a rate of inactivation (kinact) of 0.15 min(-1) and by an inactivation potency (KI) of 20 microM. In addition, the inhibition of P450 3A4 by 4-ipomeanol was NADPH-dependent and irreversible. Glutathione, catalase, and superoxide dismutase failed to protect P450 3A4 from inactivation by 4-ipomeanol. The presence of testosterone, a substrate of P450 3A4, protected the enzyme from inactivation. The estimated partition ratio of the inactivation was approximately 257. Covalent binding studies demonstrated that reactive metabolites of 4-ipomeanol modified P450 3A4 but not P450 reductase (EC 1.6.2.4). The stoichiometry of binding between reactive metabolites of radiolabeled 4-ipomeanol and P450 3A4 was approximately 1.5:1. In addition to P450 3A4, reactive metabolites of 4-ipomeanol were found to covalently bind to other proteins. 4-Ipomeanol failed to inactivate P450 1A2 in human liver microsomes. In conclusion, 4-ipomeanol irreversibly inhibited P450 3A4, and it was characterized as a mechanism-based inactivator of P450 3A4. This finding facilitates the understanding of the mechanism of bioactivation of 4-ipomeanol by human hepatic enzymes.Keywords
This publication has 8 references indexed in Scilit:
- CYP3A4 drug interactions: correlation of 10 in vitro probe substratesBritish Journal of Clinical Pharmacology, 1999
- Mechanism-Based Inactivation of Human Cytochrome P450 1A2 by Furafylline: Detection of a 1:1 Adduct to Protein and Evidence for the Formation of a Novel Imidazomethide IntermediateBiochemistry, 1998
- The Emerging Role of Cytochrome P450 3A in PsychopharmacologyJournal of Clinical Psychopharmacology, 1995
- Metabolism of Drugs by Cytochrome P450 3A IsoformsClinical Pharmacokinetics, 1995
- Reactive intermediates and their toxicological significanceToxicology, 1988
- Protective role of endogenous pulmonary glutathione and other sulfhydryl compounds against lung damage by alkylating agentsBiochemical Pharmacology, 1982
- Comparison of ratios of covalent binding to total metabolism of the pulmonary toxin, 4-ipomeanol, In vitro in pulmonary and hepatic microsomes, and the effects of pretreatments with phenobarbital or 3-methylcholanthreneBiochemical and Biophysical Research Communications, 1980
- Esters of Methanesulfonic Acid as Irreversible Inhibitors of AcetylcholinesteraseJournal of Biological Chemistry, 1962